Chiliza, B.Ojagbemi, A.Esan, O.B.Asmal, L.Oosthuizen, P.Kidd, M.Gureje, O.Emsley, R.2026-02-2620161751-78851751-7893ui_art_chiliza_combining_2016Early Intervention in Psychiatry 10(1), pp. 54-62https://repository.ibadanedu.com/handle/123456789/12569Aim: To assess the feasibility and effectiveness of depot antipsychotic (flupentixol decanoate) combined with an assertive monitoring programme (AMP) in first-episode schizophrenia. Methods: This was a prospective, non-comparative, longitudinal study conducted over 12 months assessing patient acceptance, adherence, outcome in domains of psychopathology, functionality and quality of life, and tolerability. Results: Of 207 participants, 149 (72%) completed 12 months of treatment. Acceptance of and adherence to depot was good. Treatment response was achieved by 170 (82%) participants and remission by 124 (60%). Thirty-three (19%) responders relapsed and10(5%) participants met a priori criteria for treatment resistance. Treatment was generally well tolerated. Conclusions: Combination of depot antipsychotic with an AMP maybe an effective and safe intervention linearly phase of schizophrenia, and may be particularly suitable for resource constrained settings.enAntipsychoticDeveloping countryPsychotic disorderSchizophrenia.Article